Johnson & Johnson would later say, “It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO (bedaquiline), our medicine for MDR-TB.” But I would challenge them to look into Isatu’s eyes and tell her that J&J’s price gouging had nothing to do with a medicine funded primarily by the public being unavailable to the most vulnerable members of that public. In fact, many people have died waiting for bedaquiline.
